Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer

References

• JemalASiegelRXuJWardECancer statisticsCA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• ParkinDMFernándezLMUse of statistics to assess the global burden of breast cancerBreast J200612Suppl 1S70S8016430400
   PubMed Web of Science ®Google Scholar
• GiordanoSHBuzdarAUSmithTLKauSWYangYHortobagyiGNIs breast cancer survival improving?Cancer2004100445214692023
   PubMed Web of Science ®Google Scholar
• KenneckeHYerushalmiRWoodsRMetastatic behavior of breast cancer subtypesJ Clin Oncol2010283271327720498394
   PubMed Web of Science ®Google Scholar
• GianniLNortonLWolmarkNSuterTMBonadonnaGHortobagyiGNRole of anthracyclines in the treatment of early breast cancerJ Clin Oncol2009274798480819687331
   PubMed Web of Science ®Google Scholar
• MartínMSeguíMAAntónAAdjuvant docetaxel for high-risk, node-negative breast cancerN Engl J Med20103632200221021121833
   PubMed Web of Science ®Google Scholar
• LoeschDGrecoFASenzerNNPhase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancerJ Clin Oncol2010282958296520479419
   PubMed Web of Science ®Google Scholar
• BedardPLDi LeoAPiccart-GebhartMJTaxanes: Optimizing adjuvant chemotherapy for early-stage breast cancerNat Rev Clin Oncol20107223619997076
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJExtending survival with chemotherapy in metastatic breast cancerOncologist200510Suppl 3202916368868
   PubMed Web of Science ®Google Scholar
• PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol2007253407341417606974
   PubMed Web of Science ®Google Scholar
• SeoHYLeeHJWooOHPhase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancerInvest New Drugs20112936036519943080
   PubMed Web of Science ®Google Scholar
• SpielmannMLlombart-CussacAKallaSSingle-agent gemcitabine is active in previously treated metastatic breast cancerOncology20016030330711408796
   PubMed Web of Science ®Google Scholar
• RobertNJConklingPRO’RourkeMAResults of a Phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancerBreast Cancer Res Treat201112610110821188632
   PubMed Web of Science ®Google Scholar
• ChewHKDoroshowJHFrankelPPhase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancerJ Clin Oncol2009272163216919307510
   PubMed Web of Science ®Google Scholar
• MurphyCGSeidmanADEvolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanesClin Breast Cancer20099S58S6519596644
   PubMed Web of Science ®Google Scholar
• NewmanDJCraggGMBattershillCNTherapeutic agents from the sea: Biodiversity, chemo-evolutionary insight and advances to the end of Darwin’s 200th yearDiving Hyperb Med20093921622522752743
   PubMed Web of Science ®Google Scholar
• HirataYUemuraDHalichondrins: Antitumor polyether macrolides from a marine spongePure Appl Chem198658701710
   Web of Science ®Google Scholar
• TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res2001611013102111221827
   PubMed Web of Science ®Google Scholar
• PettitGRHeraldCLBoydMRIsolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella spJ Med Chem199134333933401956053
   PubMed Web of Science ®Google Scholar
• AicherTDBuszekKRFangFGTotal synthesis of halichondrin B and Norhalichondrin BJ Am Chem Soc199211431623164
   Web of Science ®Google Scholar
• StamosDPChenSSKishiYNew synthetic route to the C.14-C.38 segment of halichondrinsJ Org Chem19976275527553
   Web of Science ®Google Scholar
• WangYHabgoodGJChristWJKishiYLittlefieldBAMelvinJYStructure-activity relationships of halichondrin B analogues: Modifications at C.30+/−C.38Bioorg Med Chem Lett2000101029103210843209
   PubMed Web of Science ®Google Scholar
• BaiRLPaullKDHeraldCLMalspeisLPettitGRHamelEHalichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity dataJ Biol Chem199126615882158891874739
   PubMed Web of Science ®Google Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMol Cancer Ther200541086109516020666
   PubMed Web of Science ®Google Scholar
• DabydeenDABurnettJCBaiRComparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulinMol Pharmacol2006701866187516940412
   PubMed Web of Science ®Google Scholar
• JordanMAWilsonLMicrotubules as a target for anticancer drugsNat Rev Cancer2004425326515057285
   PubMed Web of Science ®Google Scholar
• AldayPHCorreiaJJMacromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugationBiochemistry2009487927793819586046
   PubMed Web of Science ®Google Scholar
• OkounevaTAzarenkoOWilsonLLittlefieldBAJordanMAInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMol Cancer Ther200872003201118645010
   PubMed Web of Science ®Google Scholar
• KuznetsovGTowleMJChengHInduction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389Cancer Res2004645760576615313917
   PubMed Web of Science ®Google Scholar
• KuznetsovGTenDykeKYuMJLittlefieldBAYuJLittlefieldBAAntiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitroProceedings of the annual meeting of American Association for Cancer ResearchLos Angeles, CAApril 14–18, 2007 Abstr C58
   Google Scholar
• AgoulnikSKuznetsovGTendykeKSensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin istotype expression in human breast cancer cell linesJ Clin Oncol20052316 Suppl201215774792
   PubMed Web of Science ®Google Scholar
• AlleyMCSmithACDonohueSJComparison of the relative efficacies and toxicities of halichondrin B analoguesProceedings of the 17th American Association for Cancer Research-National Cancer Institute-European Organization for Research on Cancer International ConferenceNovember 14–18, 2005 Abstr C230
   Google Scholar
• SmithJAWilsonLAzarenkoOEribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityBiochemistry2010491331133720030375
   PubMed Web of Science ®Google Scholar
• NewmanSEribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancerCurr Opin Investig Drugs2007810571066
   PubMedGoogle Scholar
• ZhangZYKingMPelletierRDWongYNDelineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4Cancer Chemother Pharmacol20086270771618431572
   PubMed Web of Science ®Google Scholar
• SynoldTWMorganRJNewmanEMA Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trialJ Clin Oncol20052316 Suppl3036
   Web of Science ®Google Scholar
• TanARRubinEHWaltonDCPhase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsClin Cancer Res2009154213421919509146
   PubMed Web of Science ®Google Scholar
• GoelSMitaACMitaMA Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res2009154207421219509177
   PubMed Web of Science ®Google Scholar
• MinamiHMukoharaTNagaiSMukaiHNamikiMA Phase 1study of eribulin mesylate (E7389) in patients with refractory cancersProceeding of 20th American Association for Cancer Research-National Cancer Institute-European Organization for Research on Cancer Symposium on Molecular Targets and Cancer TherapeuticsGeneva, SwitzerlandOctober 21–24, 2008 Abstr 446
   Google Scholar
• WitteveenPMarchettiSMergui-RoelvinkMEribulin mesylate pharmacokinetics in patients with hepatic impairmentJ Clin Oncol2010282582
   Web of Science ®Google Scholar
• GuptaAMouldDRReydermanLPopulation pharmacokinetic-pharmacodynamic (PK/PD) analysis of safety and efficacy of eribulin in metastatic or locally advanced breast cancer patientsProceedings of European Society of Medical Oncology annual meetingStockholm, SwedenSeptember 12–16, 2008 Abstr 446
   Google Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol2009272954296119349550
   PubMed Web of Science ®Google Scholar
• CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol2010283922392820679609
   PubMed Web of Science ®Google Scholar
• IwataHAogiKMasudaNEfficacy and safety of eribulin in Japanese patients with advanced breast cancerJ Clin Oncol2010281081
   Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDA Phase III open-label randomised study (EMBRACE) of eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancerLancet201137791492321376385
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govE7389 versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes and refractory to the most recent chemotherapy Available at: http://clinicaltrials.gov/show/nct00337103Accessed May 20, 2011
   Google Scholar
• TwelvesCCortesJVahdatLTWandersJAkereleCKaufmanPAPhase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerClin Breast Cancer20101016016320299316
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast cancer Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govA Phase 1b/2, multicenter, randomized, open-label, dose-escalation and confirmation study of eribulin in combination with capecitabine Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govDose dense doxorubucin and cyclophosphamide followed by eribulin mesylate for the adjuvant treatment of early stage breast cancer Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govA study of single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor two (HER2) negative breast cancer Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govEribulin with trastuzumab as first-line therapy for locally recurrent or metastatic HER2 positive breast cancer Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govA study of CDX-011 (CR011-vcMMAE) in patients with advanced GPNMB-expressing breast cancer Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govCompassionate use of eribulin for the treatment of advanced breast cancer refractory to all other marketed therapies Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• ClinicalTrials.govAn open-label, multi-center, expanded access program with eribulin for the treatment of advanced breast cancer refractory Available at: www.clinicaltrials.govAccessed May 20, 2011
   Google Scholar
• SchoffskiPRay-CoquardILCioffiAActivity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052)J Clin Oncol20102810031
   Web of Science ®Google Scholar